A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world

Yue Shi, Min Ji, Yingying Jiang, Rong Yin, Zihan Wang, Hang Li, Shuaiyu Wang, Kang He, Yuxin Ma, Zhitong Wang, Jianwei Lu, Meiqi Shi, Bo Shen, Guoren Zhou, Tracy L. Leong, Xiaohua Wang, Cheng Chen, Jifeng Feng